endpoint,arm,time_months,n_risk
OS,Pembrolizumab,0.0,154
OS,Pembrolizumab,3.0,136
OS,Pembrolizumab,6.0,121
OS,Pembrolizumab,9.0,82
OS,Pembrolizumab,12.0,39
OS,Pembrolizumab,15.0,11
OS,Pembrolizumab,18.0,2
OS,Pembrolizumab,21.0,0
OS,Chemotherapy,0.0,151
OS,Chemotherapy,3.0,123
OS,Chemotherapy,6.0,106
OS,Chemotherapy,9.0,64
OS,Chemotherapy,12.0,34
OS,Chemotherapy,15.0,7
OS,Chemotherapy,18.0,1
OS,Chemotherapy,21.0,0
